A Centenarian Probiotic Slashed Lung Scarring by 40% in Aging Mice

Pulmonary fibrosis is a slow-motion catastrophe: scar tissue gradually replaces healthy lung, and by the time most patients receive a diagnosis, effective options are few. Age is the dominant risk factor, and approved drugs like nintedanib and pirfenidone carry serious side effects and steep costs. New research published in Aging Cell offers an early but intriguing alternative: a probiotic strain called Lactobacillus paracasei L9, originally isolated from healthy centenarians, reduced lung fibrosis scores by 30% and collagen fiber deposition by 40% in aged mice, apparently by remodeling gut bacteria and dampening a specific inflammatory pathway in the lungs. The findings are preliminary, but the mechanistic chain they reveal is unusually specific.

L9 Probiotic Reduces Collagen Scarring in Aging Mouse Lungs

In the study, researchers led by Bi R and colleagues administered L9 (4 × 10⁹ CFU/mL) orally for nine months to 15-month-old C57BL/6J mice, an age that corresponds to late middle age in humans. Lung tissue staining showed a 30% drop in fibrosis scores by the Ashcroft scale and a 40% reduction in collagen fiber deposition compared to untreated aged controls. Digging into which collagen was affected, the team found L9 cut Collagen I (Col-I) levels by 59% while leaving Collagen III largely unchanged. Alpha-smooth muscle actin (α-SMA), a marker of activated myofibroblasts that drive scarring, also fell significantly. The probiotic also reduced expression of senescence markers p21 and p16 in the lungs, suggesting some reversal of cellular aging alongside the structural improvements.

The Col-I reduction traced to two complementary mechanisms. First, PINP (procollagen I N-terminal propeptide), a marker of active Col-I synthesis, fell by 61%, indicating that L9 primarily blocked new collagen production rather than accelerating its breakdown. Second, lysyl oxidase (LOX), an enzyme that cross-links collagen fibers to make them permanent, dropped by 27% in tissue around the trachea. Less collagen made, and less of it locked into place.

Why Age-Related Pulmonary Fibrosis Is So Hard to Treat

Pulmonary fibrosis predominantly affects people over 60, and its course is relentless: median survival after diagnosis runs roughly three to five years. The existing drug options slow progression but do not reverse damage, and research into stem cell therapy and immunomodulatory agents has yet to produce a treatment that can restore lost lung function. A dietary intervention that works through the gut rather than directly on the lung would sidestep many of the toxicity concerns tied to systemic immunosuppressants, which is part of what makes the L9 findings worth attention, even at this early stage.

How Gut Bacteria Reprogram Lung Immune Cells

The mechanism connecting a swallowed probiotic to lung scarring runs through the gut-lung axis, a bidirectional communication pathway linking the gut microbiome, immune system, and respiratory tract. L9 treatment shifted the gut microbial profile toward short-chain fatty acid (SCFA) producers, including Blautia, norank_f__Lachnospiraceae, and Colidextribacter. Fecal SCFA analysis confirmed large increases: propionic acid rose 74% and butyric acid 64% in stool. More tellingly, serum levels of those same acids climbed even more sharply, with propionic acid up 97% and butyric acid up 193%, and both correlated positively with improvements in fibrosis measures.

SCFAs were undetectable in lung tissue itself, ruling out a local effect and pointing instead to a systemic immune route. In vitro, the team exposed naive CD4+ T cells to propionic acid and butyric acid and found that both suppressed Th17 cell differentiation and IL-17A secretion, with butyric acid showing the stronger effect. Back in the mice, L9 treatment cut Th17 cell numbers in lung tissue by 71% and reduced pulmonary IL-17A levels by 32%. The team also saw drops in IL-6, IL-1β, and TGFβ1, cytokines that collectively fuel the fibrotic environment.

This gut-to-lung immune suppression converges on a specific molecular pathway in pulmonary fibroblasts. IL-17A, working through its receptor IL-17RA on fibroblast surfaces, activates a JNK signaling cascade that ultimately switches on heat shock protein 47 (HSP47), a molecular chaperone required for correct folding of procollagen I. L9 suppressed JNK phosphorylation by 85% and reduced expression of upstream JNK activators TAK1 (by 50%), HPK1 (by 41%), and ASK1 (by 31%). HSP47 expression fell 61%. The team validated this IL-17RA – JNK – HSF1 – HSP47 axis using siRNA knockdown of IL-17RA, JNK1, and JNK2 in NIH/3T3 fibroblasts, confirming that each node in the chain is necessary for IL-17A to drive collagen production. Another Lactobacillus strain, LP03, has shown similar gut-mediated fibrosis reduction in bleomycin-induced mice, though through a different molecular route involving palmitoylethanolamide, suggesting gut microbiota manipulation may represent a broader strategy for lung protection.

Key Caveats Before This Reaches Patients

Several important limits apply. The study used naturally aged mice, not a bleomycin injury model, which is a strength for clinical relevance, but it is still a rodent study. SCFAs were below detection limits in lung tissue using standard GC-MS, meaning the precise step where circulating SCFAs influence circulating Th17 cells remains to be mapped with higher-sensitivity methods. The authors also acknowledge that other microbiome-derived factors, including bacterial extracellular vesicles and secondary bile acids, could be contributing to the observed immunomodulation alongside SCFAs.

Inter-individual variability in gut microbiota composition is likely to matter clinically: patients with low baseline SCFA-producing bacteria or a dysbiotic, Th17-promoting flora may respond differently to L9 supplementation. The researchers call for prospective human cohorts with matched fecal metabolomics and bronchoalveolar lavage profiling to determine whether the SCFA-Th17 axis operates the same way in aging human lungs.

What a Human Trial of L9 Would Need to Establish

The authors lay out a clear next-step agenda. Safety and efficacy trials in pulmonary fibrosis patients stratified by gut microbiota profile are the priority: identifying who is likely to respond before dosing would make trials both more efficient and more interpretable. Precision nutrition approaches that combine L9 with dietary fiber substrates that favor SCFA-producing bacteria could amplify the effect, though that hypothesis is untested. The nine-month treatment window in mice, corresponding to roughly years of human supplementation, also raises practical questions about adherence and delivery that clinical development will need to address. For now, L9 joins a small set of microbial interventions that have shown mechanistically coherent, quantifiable effects on lung scarring in animal models, a narrow but growing category that warrants the investment in human data.

Evidence rating

INVESTIGATIONAL — 75/100

Caveats:

• All findings are from a mouse model only — no human clinical data exists for this probiotic strain in pulmonary fibrosis.
• Funding source was not disclosed by the authors, so independent verification of this limitation is not possible.
• The proposed gut-to-lung SCFA mechanism is inferred from systemic serum levels; SCFAs were undetectable in lung tissue itself, leaving the precise delivery route unproven.
• Results have not been independently replicated by other research groups.

Preclinical mouse study (aged C57BL/6J mice, 9-month intervention) with supporting in vitro mechanistic work. Demonstrates association between L9 administration and reduced pulmonary fibrosis markers, with a detailed proposed causal chain, but causation in humans cannot be established from animal data alone. No independent replication in a separate cohort or species has been reported.